Zacks Research Downgrades LeMaitre Vascular (NASDAQ:LMAT) to Hold

Posted by Brian Himes on Jul 8th, 2026

LeMaitre Vascular (NASDAQ:LMAT – Get Free Report) was downgraded by stock analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a research note issued on Monday,Zacks.com reports.

LMAT has been the topic of a number of other reports. Wall Street Zen upgraded shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a research report on Saturday. Barrington Research reissued an “outperform” rating and issued a $120.00 price target on shares of LeMaitre Vascular in a report on Wednesday, June 3rd. Citizens Jmp boosted their price objective on shares of LeMaitre Vascular from $118.00 to $127.00 and gave the stock a “market outperform” rating in a research report on Wednesday, May 6th. Weiss Ratings downgraded LeMaitre Vascular from a “buy (b)” rating to a “buy (b-)” rating in a report on Tuesday, June 30th. Finally, Wells Fargo & Company increased their price objective on LeMaitre Vascular from $94.00 to $104.00 and gave the company an “equal weight” rating in a research report on Wednesday, May 6th. Four equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, LeMaitre Vascular presently has a consensus rating of “Moderate Buy” and a consensus target price of $112.60.

Get Our Latest Analysis on LeMaitre Vascular

LeMaitre Vascular Stock Performance

Shares of NASDAQ:LMAT opened at $105.70 on Monday. The business has a fifty day moving average of $98.45 and a 200-day moving average of $97.58. The company has a debt-to-equity ratio of 0.42, a quick ratio of 12.20 and a current ratio of 14.32. LeMaitre Vascular has a twelve month low of $79.00 and a twelve month high of $118.01. The firm has a market cap of $2.42 billion, a PE ratio of 39.00, a price-to-earnings-growth ratio of 2.88 and a beta of 0.52.

LeMaitre Vascular (NASDAQ:LMAT – Get Free Report) last issued its quarterly earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.66 by $0.02. LeMaitre Vascular had a net margin of 24.35% and a return on equity of 15.36%. The business had revenue of $66.55 million for the quarter, compared to the consensus estimate of $66.67 million. During the same quarter in the prior year, the company earned $0.48 EPS. The firm’s quarterly revenue was up 11.1% on a year-over-year basis. LeMaitre Vascular has set its FY 2026 guidance at 2.930-3.080 EPS and its Q2 2026 guidance at 0.790-0.840 EPS. On average, equities research analysts predict that LeMaitre Vascular will post 3 EPS for the current fiscal year.

Insider Buying and Selling

In other LeMaitre Vascular news, Director Bridget A. Ross sold 5,044 shares of the firm’s stock in a transaction that occurred on Thursday, May 7th. The shares were sold at an average price of $111.10, for a total value of $560,388.40. Following the transaction, the director directly owned 3,942 shares of the company’s stock, valued at approximately $437,956.20. This trade represents a 56.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO George W. Lemaitre sold 27,881 shares of LeMaitre Vascular stock in a transaction on Friday, May 8th. The stock was sold at an average price of $108.69, for a total transaction of $3,030,385.89. Following the sale, the chief executive officer directly owned 1,430,019 shares of the company’s stock, valued at $155,428,765.11. This represents a 1.91% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 54,453 shares of company stock valued at $5,906,174 over the last ninety days. Insiders own 7.40% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. M&T Bank Corp grew its holdings in LeMaitre Vascular by 2,240.5% during the fourth quarter. M&T Bank Corp now owns 398,069 shares of the medical instruments supplier’s stock valued at $32,283,000 after purchasing an additional 381,061 shares during the period. Goldman Sachs Group Inc. raised its holdings in LeMaitre Vascular by 144.4% in the fourth quarter. Goldman Sachs Group Inc. now owns 391,254 shares of the medical instruments supplier’s stock worth $31,731,000 after purchasing an additional 231,157 shares during the period. Bessemer Group Inc. boosted its position in shares of LeMaitre Vascular by 292.3% during the first quarter. Bessemer Group Inc. now owns 171,838 shares of the medical instruments supplier’s stock worth $18,759,000 after purchasing an additional 128,033 shares in the last quarter. Millennium Management LLC grew its holdings in shares of LeMaitre Vascular by 119.8% in the 1st quarter. Millennium Management LLC now owns 211,222 shares of the medical instruments supplier’s stock valued at $17,722,000 after buying an additional 115,141 shares during the period. Finally, First Trust Advisors LP grew its holdings in shares of LeMaitre Vascular by 13.4% in the 4th quarter. First Trust Advisors LP now owns 940,140 shares of the medical instruments supplier’s stock valued at $76,245,000 after buying an additional 111,193 shares during the period. 84.64% of the stock is currently owned by institutional investors.

LeMaitre Vascular Company Profile

(Get Free Report)

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.